Tag Archives: Myriad

‘Gene Patents’ Stifle Research?

'Gene Patents' Stifle Research?

The Federal Trade Commission has noted that “concern previously centered on the belief that biotechnology patent protection was too strong” and “would actually obstruct commercialization on new products, thereby hindering follow-on innovation.  This problem has yet to materialize.  The reasons for this are numerous and are often straightforward matters of basic economics. In addition to licensing being widely available, researchers make use of a variety [of] strategies to develop working solutions to the problem of Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Debunking the Myth: Your Genes are Patented

MYTH: YOUR GENES ARE PATENTED. FACTS: IT IS NOT POSSIBLE TO PATENT YOUR GENES The term “gene patent” is a misnomer, because genes as they exist in the body cannot be patented. Because a naturally-occurring gene – even a newly-discovered one – cannot be patented, patents don’t provide ownership rights over our genes, and nobody can infringe a patent by having a certain gene, or by passing it on to their children. If genes aren’t Read More >

Patently BIOtech  |  2 Comments  |  Email This Post
Tags: , , , , , , , , , ,

Media Coverage of BIO’s Intellectual Property Conference in Seattle

Stanford v. Roche: An Academic/Industry Collaboration Gone Wrong A Landmark Case: The Aftermath of Myriad Genetics Ethical Issues: Staying in the Frying Pan and out of the Fire

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Myriad Oral Argument Review and Analysis by Patent Docs

Great comprehensive review of oral arguments at the federal circuit in the Myriad case by Kevin Noonan of Patent Docs.

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , ,

BIO’s Intellectual Property Counsels Committee Seattle Meeting Topics

Join us for BIO’s Intellectual Property Counsels Committee Meeting in Seattle April 13-15.  You can find the session topics below. Whose Rights Are They, Anyway? Implications from and a Discussion on Stanford v. Roche The pending Supreme Court review of Stanford v. Roche has brought out multiple perspectives on the disposition of ownership rights in federally funded inventions under Bayh-Dole. This session will explore the different interpretations of the Act’s provisions, and their practical implications Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , , ,